Evidence map›Paper›PMID 38035268›Full record

ArticleFrontiers in aging neuroscience2023

Protection against Aβ-induced neuronal damage by KU-32: PDHK1 inhibition as important target.

Ranu Pal, Dongwei Hui, Heather Menchen, Huiping Zhao, Olivier Mozziconacci, Heather Wilkins, Brian S J Blagg, Christian Schöneich, Russell H Swerdlow, Mary L Michaelis and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ranu PalHiguchi Biosciences Center, University of Kansas, Lawrence, KS, United States.
Dongwei HuiHiguchi Biosciences Center, University of Kansas, Lawrence, KS, United States.
Heather MenchenHiguchi Biosciences Center, University of Kansas, Lawrence, KS, United States.
Huiping ZhaoDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS, United States.
Olivier MozziconacciUniversity of Kansas Alzheimer's Disease Research Center, University of Kansas Medical Center, Kansas City, KS, United States.
Heather WilkinsUniversity of Kansas Alzheimer's Disease Research Center, University of Kansas Medical Center, Kansas City, KS, United States.
Brian S J BlaggDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS, United States.
Christian SchöneichDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Russell H SwerdlowUniversity of Kansas Alzheimer's Disease Research Center, University of Kansas Medical Center, Kansas City, KS, United States.
Mary L MichaelisHiguchi Biosciences Center, University of Kansas, Lawrence, KS, United States.
Elias K MichaelisHiguchi Biosciences Center, University of Kansas, Lawrence, KS, United States.
University of Kansas · USUniversity of Kansas Medical Center · USUniversity of Notre Dame · US

Funding

University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BROOKS, WILLIAM M. · 2011 to 2020
$16.6M
SARCOPENIA AND APOPTOSIS: ROLE OF SERCA AND BCL-2P01AG012993 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI WILLIAMS, TODD D · 1995 to 2012
$14.0M
NIA NIH HHS P01 AG012993NIA NIH HHS P30 AG035982
6 · The paper itself

Abstract

A feature of most neurodegenerative diseases is the presence of "mis-folded proteins" that form aggregates, suggesting suboptimal activity of neuronal molecular chaperones. Heat shock protein 90 (Hsp90) is the master regulator of cell responses to "proteotoxic" stresses. Some Hsp90 modulators activate cascades leading to upregulation of additional chaperones. Novobiocin is a modulator at the C-terminal ATP-binding site of Hsp90. Of several novobiocin analogs synthesized and tested for protection against amyloid beta (Aβ)-induced neuronal death, "KU-32" was the most potent in protecting primary neurons, but did not increase expression of other chaperones believed to help clear misfolded proteins. However, KU-32 reversed Aβ-induced superoxide formation, activated Complex I of the electron transfer chain in mitochondria, and blocked the Aβ-induced inhibition of Complex I in neuroblastoma cells. A mechanism for these effects of KU-32 on mitochondrial metabolism appeared to be the inhibition of pyruvate dehydrogenase kinase (PDHK), both in isolated brain mitochondria and in SH-SY5Y cells. PDHK inhibition by the classic enzyme inhibitor, dichloroacetate, led to neuroprotection from Aβ

Indexed as

complex ImitochondriaNovobiocin analogpyruvate dehydrogenase kinasesuperoxide

Identifiers

PMID38035268
PMCPMC10682733
OpenAlexW4388656113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.